These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 30782263

  • 1. Risk factors for decreased teicoplanin trough concentrations during initial dosing in critically ill patients.
    Yoshida T, Yoshida S, Okada H, Suzuki A, Niwa T, Suzuki K, Ohmori T, Kobayashi R, Baba H, Suzuki K, Murakami N, Itoh Y, Ogura S.
    Pharmazie; 2019 Feb 01; 74(2):120-124. PubMed ID: 30782263
    [Abstract] [Full Text] [Related]

  • 2. A simplified chart for determining the initial loading dose of teicoplanin in critically ill patients.
    Yoshida S, Suzuki A, Ohmori T, Niwa T, Okada H, Suzuki K, Kobayashi R, Doi T, Kitaichi K, Matsuura K, Murakami N, Ogura S, Itoh Y.
    Pharmazie; 2017 Jan 10; 72(1):53-57. PubMed ID: 29441898
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.
    Barbot A, Venisse N, Rayeh F, Bouquet S, Debaene B, Mimoz O.
    Intensive Care Med; 2003 Sep 10; 29(9):1528-34. PubMed ID: 12856119
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M, Chida K, Suda T, Muramatsu H, Suzuki Y, Hashimoto H, Gemma H, Nakamura H.
    J Infect Chemother; 2006 Aug 10; 12(4):185-9. PubMed ID: 16944256
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Teicoplanin pharmacokinetics in critically ill paediatric patients.
    Sánchez A, López-Herce J, Cueto E, Carrillo A, Moral R.
    J Antimicrob Chemother; 1999 Sep 10; 44(3):407-9. PubMed ID: 10511412
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Variations of teicoplanin concentrations in neutropenic patients.
    Gimenez F, Leblond V, Nguyen J, Serrand P, Binet JL, Grosset J, Thuillier A.
    J Clin Pharm Ther; 1997 Jun 10; 22(3):187-90. PubMed ID: 9447473
    [Abstract] [Full Text] [Related]

  • 16. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ, Egan S, Fennell JP, O'Byrne P, Enright H, Deasy E, Ryder SA, D'Arcy DM, McHugh J.
    Int J Antimicrob Agents; 2015 Oct 10; 46(4):406-12. PubMed ID: 26228465
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ, Parton T, McWhinney B, Fennell JP, O'Byrne P, Deasy E, Egan S, Enright H, Desmond R, Ryder SA, D'Arcy DM, McHugh J, Roberts JA.
    J Antimicrob Chemother; 2018 Apr 01; 73(4):995-1003. PubMed ID: 29272419
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
    Wang T, Li N, Hu S, Xie J, Lei J, Wang Y, Zheng X, Xing J, Dong Y.
    Int J Clin Pharmacol Ther; 2015 May 01; 53(5):356-62. PubMed ID: 25828639
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.